FDA celebrates DExEU pay rises of up to 11%
The FDA has secured pay rises of up to 11% for members in the Department for Exiting the European Union (DExEU).
Following talks with the union, the department has offered its staff an average consolidated pay increase of 7.6%, rising to up to 11% for those on the bottom of the pay scale.
DExEU have also increased allowances for specialists. Accountants, analysts and economists will receive up to £5,000 in recognition of their skills and experience.
FDA members based in DExEU voted unanimously to accept the pay offer, which was warmly welcomed by National Officer Victoria Jones.
“Civil servants in DExEU are working flat out to deliver the will of the Government ahead of the UK leaving the EU and deserve every penny of this pay rise,” she said, “which comes after almost 10 years of wage stagnation.”
Jones then called on other government departments to follow DExEU’s example.
“From HMRC to the Home Office,” she explained, “civil servants have risen to the challenge of preparing for Brexit, whatever form it may take, while also ensuring the day to day business of government continues.
“At this crucial time for our country, it is essential that the civil service can recruit and retain the best staff for the job,” Jones continued, “and that can only be achieved if they are paid what they are worth. DExEU has recognised this undeniable fact and it’s high time other departments follow suit.”
Jones’s comments were reported in Civil Service World.
Related News
-
Why we need an independent pay review body for delegated grades
Assistant General Secretary Lauren Crowley outlines the FDA’s response to this week’s pay announcements and shares the FDA’s long-term plans for civil service pay.
-
A different approach
With civil service pay largely unchanged for the last 30 years, Dave Penman outlines why the next government should make long-term reform an early priority.
-
FDA calls for substantial reform of NCA pay structure
In its evidence to the National Crime Agency Pay Review Body the FDA argues for urgent reform of the NCA pay structure.